Verve Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Verve Therapeutics, Inc. The largest reported stake is Pentwater Capital Management LP's, at 7.5%. 3 filings are on record since July 28, 2025 (Schedule 13G, August 14, 2025).

Pentwater Capital Management LP also filed stake reports on 20 other companies ↓

Sell to companies like Verve Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2025-08-14 · Reporting person: Pentwater Capital Management LP · Sole voting: 0 · Shared voting: 6,720,000 · Sole dispositive: 0 · Shared dispositive: 6,720,000 · SCHEDULE 13G, 2025-08-14
• Filing 2025-08-14 · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-08-14
• Filing 2025-07-28 · Reporting person: Gv 2017, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-07-28

Verve Therapeutics, Inc. has 3 Schedule 13D or 13G filings on record since 2025-07-28. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Verve Therapeutics, Inc. and the warning signs.

See Verve Therapeutics, Inc.'s free Snapshot Watch Verve Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Verve Therapeutics, Inc. and the records around it.

Companies that share a holder

• Pentwater Capital Management LP also filed stake reports on 20 other companies: AMC Entertainment Holdings, Inc. (Aug 2026), Caesars Entertainment, Inc. (Aug 2026), Centessa Pharmaceuticals plc (Aug 2026)
• BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)

Want the whole picture on Verve Therapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Verve Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Verve Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   3 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing names Verve Therapeutics, Inc., with its principal executive office as 201 BROOKLINE AVENUE, SUITE 601, BOSTON, MA 02215 (SCHEDULE 13G, 2025-08-14).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Verve Therapeutics, Inc.

Who owns Verve Therapeutics, Inc.?

On this page, one holder's latest ownership filing reports 5% or more of Verve Therapeutics, Inc.: Pentwater Capital Management LP (7.5%, Schedule 13G, filed 2025-08-14).

When did Pentwater Capital Management LP buy into Verve Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Pentwater Capital Management LP on this page is the Schedule 13G, filed 2025-08-14, reporting 7.5%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Verve Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Verve Therapeutics, Inc. is mentioned again
• Find former Verve Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes